Nicht muskelinvasives Blasenkarzinomrezidiv: Gemcitabine/Docetaxel-Instillation

Ein Rezidiv eines nicht muskelinvasiven Harnblasenkarzinoms nach intravesikaler BCG (Bacillus Calmette-Guérin)-Behandlung stellt eine therapeutische Herausforderung dar. Patienten, die eine radikale Zystektomie mit Harnableitung ablehnen oder welchen eine solche Operation nicht zugemutet werden kann, profitieren vermutlich von einer intravesikalen Rescue-Therapie mit Gemcitabine und Docetaxel, berichten nordamerikanische Wissenschaftler.

Publication History

Article published online:
07 April 2021

• Literatur

• 1 Hautmann RE, de Petriconi RC, Pfeiffer C. et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012; 61: 1039-1047
• 2 Arends TJ, Nativ O, Maffezzini M. et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016; 69: 1046-1052
• 3 Di Stasi SM, Giannantoni A, Giurioli A. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43-51
• 4 Steinberg RL, Thomas LJ, Brooks N. et al. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol 2020; 203: 902-909
• 5 Retz M, Gschwend JE, Maisch P. [Short version of the German S3 guideline for bladder cancer]. Urologe A 2016; 55: 1173-1187
• 6 Babjuk M, Bohle A, Burger M. et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017; 71: 447-461
• 7 Kramer M, Gakis G. Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer. . Urologe A 2020, in print
• 8 Balar A, Kulkarni G, Uchio E. et al. Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results, ASCO GU. San Francisco: 2019
• 9 Addeo R, Caraglia M, Bellini S. et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; 28: 543-548
• 10 Di Lorenzo G, Perdona S, Damiano R. et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116: 1893-1900
• 11 Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol 2013; 189: 834-839
• 12 Sousa A, Inman BA, Pineiro I. et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia 2014; 30: 166-170
• 13 Sousa A, Pineiro I, Rodriguez S. et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia 2016; 32: 374-380
• 14 Dinney C. et al. A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), SUO-CTC. Washington D.C: 2019
• 15 Lerner SP, Bajorin DF, Dinney CP. et al. Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2016; 2: 165-202